Co-Diagnostics (C970) Stock Statistics & Valuation Metrics

Co-Diagnostics has a market cap or net worth of €4.33M. The enterprise value is -€8.91M.

Co-Diagnostics has 3,602,465 shares outstanding. The number of shares has decreased by -2.65% in one year.

Co-Diagnostics’s return on equity (ROE) is -2.27 and return on invested capital (ROIC) is -139.21%.

The current PE Ratio of Co-Diagnostics is ―. Co-Diagnostics’s PEG ratio is 0.03.

In the last 12 months, Co-Diagnostics had revenue of 418.20K and earned -46.90M in profits. Earnings per share was -35.25.

In the last 12 months, operating cash flow was -29.14M and capital expenditures -700.05K, giving a free cash flow of -29.84M billion.

Co-Diagnostics pays an annual dividend of ―, resulting in a dividend yield of ―

Co-Diagnostics upcoming earnings date is May 7, 2026, Before Open (Confirmed).

Co-Diagnostics as a current ratio of 3.87, with Debt / Equity ratio of 5.99%

In the past 12 months, Co-Diagnostics has paid -1.62M in taxes.

Co-Diagnostics EV to EBITDA ratio is 0.13, with an EV/FCF ratio of 0.13.

Co-Diagnostics has €11.88M in cash and marketable securities with €1.24M in debt, giving a net cash position of €10.65M billion.

Gross margin is -217.83%, with operating margin of -7529.23%, and net profit margin of -11213.62%.

The average price target for Co-Diagnostics is €4.25, which is 11.43% higher than the current price. The consensus rating is Hold